The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Beyond the label: optimal dosing strategies for CML in community practice
Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses dosing strategies for chronic myeloid leukemia (CML) treatment in community practice. Dr Haddad explains that while clinicians often use FDA-approved or label-recommended doses, some patients may achieve optimal responses at lower doses with fewer side effects, allowing them to remain on treatment longer and potentially improve outcomes. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For patients who do not see CML very frequently, they tend to use the treatment doses that are FDA approved or they are mentioned in the label of the drug, which sometimes might be higher than what we call optimal biologic dose. So I think don’t be afraid in a patient who has some side effects to use a lower dose, lower than what is prescribed in the drug label and lower than the drug dose that is FDA approved because many, many patients will actually respond at the lower dose and will have less side effects and potentially can remain on the treatment for a longer period of time and achieve better remissions...
For patients who do not see CML very frequently, they tend to use the treatment doses that are FDA approved or they are mentioned in the label of the drug, which sometimes might be higher than what we call optimal biologic dose. So I think don’t be afraid in a patient who has some side effects to use a lower dose, lower than what is prescribed in the drug label and lower than the drug dose that is FDA approved because many, many patients will actually respond at the lower dose and will have less side effects and potentially can remain on the treatment for a longer period of time and achieve better remissions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
